Porton Pharma Solutions News

Boteng Co., Ltd. (300363): Increased orders led to an improvement in revenue and a narrowing of losses

Ping An SecuritiesOct 25 13:01

Boteng Co., Ltd. (300363): Revenue improved month-on-month, and orders and profitability continued to show marginal improvements

huaxi SecuritiesOct 24 00:00

Boteng Co., Ltd. (300363): Quarterly losses are narrowing, and emerging businesses are progressing steadily

Aug 28 15:56

Boteng Co., Ltd. (300363): 2Q24 profit margin improved month-on-month, looking forward to order conversion

china international capital corporationAug 28 13:16

Boteng Co., Ltd. (300363) Company Information Update Report: Regular business growth is steady, profit side is under phased pressure

Apr 30 00:00

Boteng Co., Ltd. (300363): Continuing to consolidate the small molecule pipeline and expect profit margin restoration

Apr 29 13:11

Boteng Co., Ltd. (300363): Insufficient capacity utilization, short-term performance under pressure, profitability is expected to improve quarterly

Apr 29 00:00

Boteng Co., Ltd. (300363): After delivery of large orders, focus on improving capacity utilization

Jan 29 00:00

Boteng Co., Ltd. (300363): Leading domestic CDMO expects new business to enter a harvest period

Dec 5, 2023 15:02

Boteng Co., Ltd. (300363) 2023 Third Quarter Report Review: The impact of major orders has been removed, and the global production capacity layout continues to advance

Nov 30, 2023 15:02

Boteng Co., Ltd. (300363): Actively expanding the high-quality customer market and reaching a strategic cooperation with Yingli Pharmaceutical

Nov 30, 2023 00:00

Boteng Co., Ltd. (300363) Company Information Update Report: Steady Development of Regular Business, Implementation of New Production Capacity, Opening Up Space for Growth

Nov 16, 2023 00:00

Boteng Co., Ltd. (300363) 2023 Third Quarter Report Performance Review: Steady Growth in Regular Business and Gradual Implementation of New Capacity Building

Nov 5, 2023 00:00

Boteng Co., Ltd. (300363): Rapid development of conventional and steady formulation business

Nov 4, 2023 00:00

Boteng Co., Ltd. (300363): Demand for small-molecule CDMO remains strong, and new business is progressing steadily

Nov 3, 2023 00:00

Boteng Co., Ltd. (300363) 2023 Third Quarter Report Review Report: Big Orders Have Been Delivered, New Business Continues to Advance

Nov 2, 2023 00:00

Boteng Co., Ltd. (300363): The growth rate of orders for small molecule APIs is impressive, and the global layout continues to advance

Oct 31, 2023 00:00

Boteng Co., Ltd. (300363): Various businesses continue to promote the gradual implementation of new capacity building

Oct 29, 2023 00:00

Boteng Co., Ltd. (300363) Review: Major orders have been delivered, and new business is growing rapidly

Oct 29, 2023 00:00

Boteng Co., Ltd. (300363): Delivery of large orders completed, business volume contracted, Q3 fee settlement was less

Oct 29, 2023 00:00